Seeking Alpha

Available Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing

Oct. 02, 2024 8:00 AM ETAbbVie Inc. (ABBV) Per FDA requirement for this indication, Allergan Aesthetics is providing a product training program for providers, which includes facial anatomy and ...
Pharm Exec

FDA Approves AbbVie’s Juvederm Voluma XC for the Treatment of Moderate to Severe Temple Hollowing

This marks the first time that a hyaluronic acid dermal filler has received FDA approval for temple hollowing. Allergan Aesthetics, an AbbVie company, announced that the FDA has approved Juvéderm ...
Miami Herald

Juvéderm Voluma XC combats aging by lifting, sculpting and adding volume to the cheeks

Dermatologists and plastic surgeons have a new, nonsurgical weapon to add to their anti-aging arsenal. Juvéderm Voluma XC was approved by the U.S. Food and Drug Administration in December as the first ...
NBC 6 South Florida

Voluma XC: Miami Dermatologist Introduces Longer Lasting Facial Filler

Susan Schaeffer lost 30 pounds over the last couple of years and doesn't like the effect it's had on her face. "I mean I like the idea of having a thin face but not so thin that I look 20 years older, ...
Stockhouse

JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval

IRVINE, Calif., March 5, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUMA® XC for injection in the ...
Stockhouse

Available Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing

"The number one facial concern patients have is the eye area,12 so it is essential to consider treating the temples as part of a comprehensive treatment plan. With the approval and training-led launch ...